Previous close | 53.10 |
Open | 52.67 |
Bid | 52.38 x 700 |
Ask | 52.44 x 700 |
Day's range | 52.37 - 52.85 |
52-week range | 42.63 - 55.72 |
Volume | |
Avg. volume | 2,360,237 |
Market cap | 132.406B |
Beta (5Y monthly) | 0.41 |
PE ratio (TTM) | 28.79 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.04 (3.89%) |
Ex-dividend date | 09 May 2024 |
1y target est | N/A |
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.
AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.
Sanofi (SNY) posts mixed quarterly results, beating estimates for earnings while missing the same for sales. It raises its 2024 earnings growth expectations at CER.